Lee-Jen Wei

Lee-Jen Wei, David R Nelson, Lee-Jen Wei, 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Utility of Restricted Mean Survival Time Analysis for Heart Failure Clinical Trial Evaluation and Interpretation.

Lee-Jen Wei, C. O'connor, C. Specchia, 2020, JACC. Heart failure.

Prediction of survival probability based on a linear regression model

Zhiliang Ying, Lee-Jen Wei, Z. Ying, 1992 .

Quantifying the totality of treatment effect with multiple event‐time observations in the presence of a terminal event from a comparative clinical study

S. Solomon, Lee-Jen Wei, L. Tian, 2018, Statistics in Medicine.

The Optimal Confidence Region for a Random Parameter

H. Uno, Lee-Jen Wei, L. Tian, 2005 .

Intensive versus standard blood pressure control in type 2 diabetes: a restricted mean survival time analysis of a randomised controlled trial

Lee-Jen Wei, M. Najafzadeh, S. Shi, 2021, BMJ Open.

Simultaneous and Exact Interval Estimates for the Contrast of Two Groups Based on an Extremely High Dimensional Response Variable: Application to Mass Spec Data Analysis

W. Hahn, P. Kantoff, Lee-Jen Wei, 2005 .

Restricted mean survival time for the analysis of cardiovascular outcome trials assessing non-inferiority: Case studies from antihyperglycemic drug development.

Lee-Jen Wei, C. Battioui, D. Manner, 2019, American heart journal.

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer’s Disease

Richard E Thompson, D. Alkon, Lee-Jen Wei, 2018, Journal of Alzheimer's disease : JAD.

Interim analyses based on median survival times

Lee-Jen Wei, K. Keaney, 1994 .

Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases

Lee-Jen Wei, A. Torbicki, H. Ghofrani, 2019, Circulation. Cardiovascular quality and outcomes.

Axillary vs Sentinel Lymph Node Dissection in Women With Invasive Breast Cancer.

H. Uno, Lee-Jen Wei, M. Hassett, 2018, JAMA.

Risk-Benefit Comparisons Between Shorter and Longer Durations of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer.

Lee-Jen Wei, Z. McCaw, D. H. Kim, 2020, JAMA oncology.

Unifying Design and Analysis for Superiority and Noninferiority Trials With Appropriate End Point.

H. Uno, Lee-Jen Wei, B. Claggett, 2019, JAMA surgery.

Quantifying the Added Value of Low-Molecular-Weight Heparin to Intermittent Pneumatic Compression for Preventing Venous Thromboembolic Events Under the Risk-Benefit Perspective.

Lee-Jen Wei, S. Piantadosi, Z. McCaw, 2019, JAMA surgery.

Impact of Acute Serum Creatinine Elevation in Patients Treated with Nesiritide

Lee-Jen Wei, U. Elkayam, J. Heywood, 2009, Clinical cardiology.

Analysis of Response Data for Assessing Treatment Effects in Comparative Clinical Studies

L. Tian, Lee-Jen Wei, T. Choueiri, 2020, Annals of Internal Medicine.

Quantifying Treatment Effects in Trials with Multiple Event-Time Outcomes.

H. Uno, M. Pfeffer, Lee-Jen Wei, 2022, NEJM evidence.

Restricted Mean Survival Time as a Measure to Interpret Clinical Trial Results.

H. Uno, Lee-Jen Wei, D. H. Kim, 2017, JAMA cardiology.

Intensive Versus Standard Blood Pressure Lowering and Days Free of Cardiovascular Events and Serious Adverse Events: a Post Hoc Analysis of Systolic Blood Pressure Intervention Trial

Lee-Jen Wei, Jackson T. Wright, W. Cushman, 2022, Journal of General Internal Medicine.

Restricted mean survival time versus conventional measures for treatment decision‐making

Lee-Jen Wei, M. Najafzadeh, S. Shi, 2021, Journal of the American Geriatrics Society.

Quantifying and Interpreting Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Cancer Control for Advanced Gastroesophageal Cancer Among an Older Population.

Lee-Jen Wei, D. H. Kim, Xuan Wang, 2021, JAMA oncology.

Letter by McCaw et al Regarding Article, "The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease".

G. Fitzmaurice, Lee-Jen Wei, Z. McCaw, 2021, Circulation.

Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older.

Lee-Jen Wei, Z. McCaw, Daniel Li, 2020, JAMA cardiology.

Fulvestrant plus capivasertib for metastatic breast cancer.

Lee-Jen Wei, Z. McCaw, D. H. Kim, 2020, The Lancet. Oncology.

P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention.

Lee-Jen Wei, Z. McCaw, 2019, JAMA.

Trifluridine/tipiracil in metastatic gastric cancer.

Lee-Jen Wei, H. Fu, Z. McCaw, 2019, The Lancet. Oncology.

Trastuzumab Therapy for 9 Weeks vs 1 Year for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Lee-Jen Wei, F. Jiang, Z. McCaw, 2019, JAMA oncology.

Using the Restricted Mean Survival Time Difference as an Alternative to the Hazard Ratio for Analyzing Clinical Cardiovascular Studies.

Lee-Jen Wei, G. Yin, Z. McCaw, 2019, Circulation.

Biodegradable-polymer stents versus durable-polymer stents

Lee-Jen Wei, A. Orkaby, Huili Zhu, 2019, The Lancet.

Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab as a Result of Adverse Events Lived Significantly Longer Than Patients Who Continued Treatment.

H. Uno, Lee-Jen Wei, M. Horiguchi, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interpreting the Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma.

H. Uno, Lee-Jen Wei, D. H. Kim, 2018, JAMA oncology.

Zoledronic Acid Dosing in Patients With Metastatic Breast Cancer.

H. Uno, Lee-Jen Wei, T. Hasegawa, 2017, JAMA oncology.

Assessing Metronomic Chemotherapy for Progressive Pediatric Solid Malignant Tumors.

H. Uno, Lee-Jen Wei, X. Fang, 2018, JAMA oncology.

Demonstrating Noninferiority of Accelerated Radiotherapy With Panitumumab vs Standard Radiotherapy With Cisplatin in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma.

Lee-Jen Wei, David Cheng, K. Pak, 2017, JAMA oncology.

Clinical Utility Assessment of Gonadotropin-Releasing Hormone Analogs Among Women Younger Than 35 Years.

Lee-Jen Wei, Z. McCaw, 2022, JAMA oncology.

Evaluating Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma.

Lee-Jen Wei, R. Sun, Lu Tian, 2022, JAMA surgery.

Pitfall in the Design and Analysis of Comparative Oncology Trials With a Time-to-Event Endpoint and Recommendations

Lee-Jen Wei, Z. McCaw, D. H. Kim, 2022, JNCI cancer spectrum.

Quantifying the Long-term Survival Benefit of Pembrolizumab for Patients With Advanced Gastric Cancer.

Lee-Jen Wei, Z. McCaw, E. Ludmir, 2021, JAMA oncology.

Survival Analysis of Treatment Efficacy in Comparative Coronavirus Disease 2019 Studies

L. Tian, Lee-Jen Wei, A. Localio, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Progression-free survival in the ICON8 trial

Lee-Jen Wei, C. Fuller, Z. McCaw, 2020, The Lancet.

Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer.

Lee-Jen Wei, D. H. Kim, R. Sun, 2020, JAMA oncology.

Quantifying the benefit of non-small-cell lung cancer immunotherapy

Lee-Jen Wei, C. Fuller, A. Grossberg, 2019, The Lancet.

Regional Hyperthermia With Neoadjuvant Chemotherapy for Treatment of Soft Tissue Sarcoma.

Lee-Jen Wei, R. Sun, 2019, JAMA oncology.

Interpreting the Long-term Prognostic Value of Total Mesorectal Excision Plane Quality in Rectal Adenocarcinoma.

Lee-Jen Wei, Hwajeong Lee, R. Sun, 2019, JAMA surgery.

Quantifying Immunoscore performance

Lee-Jen Wei, D. H. Kim, L. Nie, 2018, The Lancet.

Evaluating Treatment Effect Based on Duration of Response for a Comparative Oncology Study

L. Tian, Lee-Jen Wei, M. Rothenberg, 2018, JAMA oncology.

Assessing the Prognostic Value of the Automated Bone Scan Index for Prostate Cancer.

Lee-Jen Wei, Huili Zhu, R. Sun, 2019, JAMA oncology.

Sex as a predictor of response to cancer immunotherapy.

Lee-Jen Wei, M. Takeuchi, Z. McCaw, 2018, The Lancet. Oncology.

Quantifying the Effect of Lower vs Higher Positive End-Expiratory Pressure on Ventilator-Free Survival in ICU Patients.

Lee-Jen Wei, Z. McCaw, Lu Tian, 2021, JAMA.

Analytical issues regarding rosiglitazone meta-analysis.

Lee-Jen Wei, B. Claggett, 2011, Archives of internal medicine.

Handling Informative Premature Treatment or Study Discontinuation for Assessing Between-Group Differences in a Comparative Oncology Trial.

Lee-Jen Wei, B. Claggett, E. Ludmir, 2022, JAMA oncology.

The Highest Confidence Density Region and Its Usage for Inferences about the Survival Function with Censored Data

Lee-Jen Wei, L. Tian, T. Cai, 2008 .

Prolylcarboxypeptidase gene, chronic hypertension, and risk of preeclampsia.

T. Niu, Xiping Xu, Lee-Jen Wei, 2006, American journal of obstetrics and gynecology.

Intensive Versus Standard Blood Pressure Lowering and Days Free of Cardiovascular Events and Serious Adverse Events: a Post Hoc Analysis of Systolic Blood Pressure Intervention Trial

Lee-Jen Wei, Jackson T. Wright, W. Cushman, 2022, Journal of General Internal Medicine.

Estimating Treatment Effect as the Primary Analysis in a Comparative Study: Moving Beyond P Value.

Lee-Jen Wei, E. Ludmir, B. Huang, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Maternal Toxicity With Continuous Nevirapine in Pregnancy: Results From PACTG 1022

Lee-Jen Wei, D. H. Watts, J. Hitti, 2004, Journal of acquired immune deficiency syndromes.

Assessment of Treatment Effect With Multiple Outcomes in 2 Clinical Trials of Patients With Duchenne Muscular Dystrophy.

Lee-Jen Wei, C. McDonald, G. Elfring, 2020, JAMA network open.

The Myth of Making Inferences for an Overall Treatment Efficacy with Data from Multiple Comparative Studies Via Meta-Analysis

M. Pfeffer, Lee-Jen Wei, B. Claggett, 2017, Statistics in Biosciences.

Quantifying the Treatment Effect of Drug-Eluting Stents Optimized for Biocompatibility vs Bare-Metal Stents With a Single Month of Dual Antiplatelet Therapy.

Lee-Jen Wei, M. Zemplenyi, 2019, JAMA cardiology.

Meta-analysis to Evaluate High-Dose Therapy Followed by Stem Cell Transplant in Patients With Multiple Myeloma.

L. Tian, Lee-Jen Wei, B. Claggett, 2018, JAMA oncology.

The Myth of Making Inferences for an Overall Treatment Efficacy with Data from Multiple Comparative Studies Via Meta-Analysis

Takahiro Hasegawa, Lee-Jen Wei, Scott D. Solomon, 2017 .

Cross-Study Analysis of the Relative Efficacies of Oral Antiviral Therapies for Chronic Hepatitis B Infection in Nucleoside-Naive Patients

Lee-Jen Wei, Lee-Jen Wei, B. Kreter, 2007, Clinical drug investigation.

REPLICATION TRIAL TO CONFIRM REVERSAL OF COGNITIVE DECLINE WITH BRYOSTATIN FOR ADVANCED ALZHEIMER’S PATIENTS IN THE ABSENCE OF MEMANTINE

Richard E Thompson, D. Alkon, Lee-Jen Wei, 2019, Alzheimer's & Dementia.

SIGNIFICANT COGNITIVE IMPROVEMENT WITH BRYOSTATIN FOR ADVANCED ALZHEIMER’S PATIENTS IN THE ABSENCE OF MEMANTINE

Richard E Thompson, D. Alkon, Lee-Jen Wei, 2018, Alzheimer's & Dementia.

Comparison of atovaquone and azithromycin with trimethoprim-sulfamethoxazole for the prevention of serious bacterial infections in children with HIV infection.

Lee-Jen Wei, R. Yogev, M. Paul, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Cox-Type Regression Analysis for Large Numbers of Small Groups of Correlated Failure Time Observations

Lee-Jen Wei, Sue Leurgans, S. Leurgans, 1992 .

dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data

Cheng Li, Ming Lin, Wing Hung Wong, 2004, Bioinform..

Evaluating longitudinal therapy effects via the North Star Ambulatory Assessment

Lee-Jen Wei, F. Muntoni, K. Flanigan, 2021, Muscle & nerve.

Combining Association Tests across Multiple Genetic Markers in Case-Control Studies

Lee-Jen Wei, Xin Xu, Huanyu Zhou, 2007, Human Heredity.

Stratifying Subjects for Treatment Selection with Censored Event Time Data from a Comparative Study

Tianxi Cai, Lihui Zhao, Hajime Uno, 2010 .

Comparing Risk Scoring Systems Beyond the ROC Paradigm in Survival Analysis

Tianxi Cai, Isaac S. Kohane, Hajime Uno, 2009 .

Predicting future responses based on possibly mis-specified working models

S. Solomon, Lee-Jen Wei, L. Tian, 2008 .

Identifying patients who need additional biomarkers for better prediction of health outcome or diagnosis of clinical phenotype

Lee-Jen Wei, L. Tian, T. Cai, 2007 .

Semiparametric Box–Cox power transformation models for censored survival observations

Tianxi Cai, Lee-Jen Wei, Lu Tian, 2005 .

Semiparametric regression analysis for clustered failure time data

Tianxi Cai, Lee-Jen Wei, Lee-Jen Wei, 2000 .

Estimating Subject-Specific Treatment Differences for Risk-Benefit Assessment with Applications to Beta-Blocker Effectiveness Trials

Lihui Zhao, L. Tian, Lee-Jen Wei, 2013 .

Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio

H. Uno, Lee-Jen Wei, M. Takeuchi, 2017, JAMA oncology.

Estimating Subject‐Specific Dependent Competing Risk Profile with Censored Event Time Observations

Yi Li, Lee-Jen Wei, Lu Tian, 2011, Biometrics.

Defining Study Outcomes That Better Reflect Individual Response to Treatment

Lee-Jen Wei, J. Lindsey, B. Claggett, 2017, The Pediatric infectious disease journal.

How to Quantify and Interpret Treatment Effects in Comparative Clinical Studies of COVID-19

L. Tian, Lee-Jen Wei, Chien-Chang Lee, 2020, Annals of Internal Medicine.

Treatment selections using risk-benefit profiles based on data from comparative randomized clinical trials with multiple endpoints.

Lee-Jen Wei, Lu Tian, Lee-Jen Wei, 2015, Biostatistics.

Practical Recommendations on Quantifying and Interpreting Treatment Effects in the Presence of Terminal Competing Risks: A Review.

S. Solomon, M. Pfeffer, Lee-Jen Wei, 2021, JAMA cardiology.

Estimating Subject-Specific Treatment Differences for Risk-Benefit Assessment with Competing Risk Event-Time Data

Lihui Zhao, Lee-Jen Wei, Lu Tian, 2011 .

Analysis of Long-term Benefits of Intensive Blood Pressure Control.

Lee-Jen Wei, Z. McCaw, D. H. Kim, 2019, JAMA.

Applying Evidence-Based Medicine to Shared Decision Making: Value of Restricted MeanSurvival Time.

Lee-Jen Wei, M. Rich, A. Orkaby, 2019, The American journal of medicine.

Pravastatin for Primary Prevention in Older Adults: Restricted Mean Survival Time Analysis

Lee-Jen Wei, M. Rich, A. Orkaby, 2018, Journal of the American Geriatrics Society.

Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy.

Lee-Jen Wei, G. Comi, R. Finkel, 2020, Journal of comparative effectiveness research.

Estimating Treatment Effect With Clinical Interpretation From a Comparative Clinical Trial With an End Point Subject to Competing Risks

Lihui Zhao, L. Tian, S. Solomon, 2018, JAMA cardiology.

Quantification of Long-term Survival Benefit in a Comparative Oncology Clinical Study

H. Uno, Lee-Jen Wei, D. Schrag, 2018, JAMA oncology.

Moving beyond our comfort zone.

M. Pfeffer, Lee-Jen Wei, B. Claggett, 2013, European heart journal.

On the Restricted Mean Event Time in Survival Analysis

Lu Tian, Lihui Zhao, Lee-Jen Wei, 2013 .

Statistical Inference for Infinite Dimensional Parameters Via Asymptotically Pivotal Estimating Functions

Lee-Jen Wei, L. Tian, M. Goldwasser, 2004 .

Comparing two failure time distributions in the presence of dependent censoring

James M. Robins, Lee-Jen Wei, Danyu Lin, 1996 .

Classical Model Selection

Lu Tian, Tianxi Cai, Lee-Jen Wei, 2013 .

Choosing clinically interpretable summary measures and robust analytic procedures for quantifying the treatment difference in comparative clinical studies

G. Fitzmaurice, Lee-Jen Wei, F. Bretz, 2021, Statistics in medicine.

Newborn Screening for Cystic Fibrosis Is Complicated by Age-Related Decline in Immunoreactive Trypsinogen Levels

Lee-Jen Wei, R. Laessig, P. Farrell, 1990, Pediatrics.

Interpreting Clinical Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer (BRPC).

Lee-Jen Wei, Z. McCaw, D. H. Kim, 2018, Annals of surgery.

Efficiency of two sample tests via the restricted mean survival time for analyzing event time observations

L. Tian, H. Uno, Lee-Jen Wei, 2018, Biometrics.

Assessing Clinical Equivalence in Oncology Biosimilar Trials With Time-to-Event Outcomes

L. Tian, H. Uno, Lee-Jen Wei, 2019, JNCI cancer spectrum.

Prevalence of Metabolic Syndrome and Its Relation to Body Composition in a Chinese Rural Population

F. Hu, Xiping Xu, Lee-Jen Wei, 2006, Obesity.

Neratinib after trastuzumab in patients with HER2-positive breast cancer.

H. Uno, Lee-Jen Wei, T. Hasegawa, 2016, The Lancet. Oncology.

Appropriate Analysis of Duration of Response Data in Cancer Trials.

Lee-Jen Wei, Z. McCaw, Lu Tian, 2020, JAMA Oncology.

Linear Regression Analysis for Multivariate Failure Time Observations

Lee-Jen Wei, Lee-Jen Wei, J. S. Lin, 1992 .

Overall survival with oral selinexor plus low‐dose dexamethasone versus real‐world therapy in triple‐class‐refractory multiple myeloma

Lee-Jen Wei, M. Dimopoulos, S. Jagannath, 2020, EJHaem.

Utility of Restricted Mean Survival Time for Analyzing Time to Nursing Home Placement Among Patients With Dementia

Lee-Jen Wei, D. H. Kim, Xihao Li, 2021, JAMA network open.

Moving beyond conventional stratified analysis to assess the treatment effect in a comparative oncology study

H. Uno, Lee-Jen Wei, F. Hong, 2021, Journal for ImmunoTherapy of Cancer.

Robust Alternatives to ANCOVA for Estimating the Treatment Effect via a Randomized Comparative Study

L. Tian, Lee-Jen Wei, L. J. Wei, 2019, Journal of the American Statistical Association.

Overall survival (OS) with oral selinexor plus low dose dexamethasone (Sd) in patients with triple class refractory-multiple myeloma (TCR-MM).

Lee-Jen Wei, M. Dimopoulos, S. Jagannath, 2019, Journal of Clinical Oncology.

Rank estimation of treatment differences based on repeated measurements subject to dependent censoring

Lee-Jen Wei, Lee-Jen Wei, D. Glidden, 1999 .

Analysis of incomplete repeated measurements with dependent censoring times

Joseph W. Hogan, Lee-Jen Wei, Lee-Jen Wei, 1998 .

Semiparametric regression for the mean and rate functions of recurrent events

Zhiliang Ying, Lee-Jen Wei, Danyu Lin, 2000 .

Evaluating Noninferiority With Clinically Interpretable Statistics for the PROSELICA Study to Assess Treatment Efficacy of a Reduced Dose of Cabazitaxel for Treating Metastatic Prostate Cancer.

H. Uno, Lee-Jen Wei, M. Horiguchi, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association Between Bariatric Surgery and All-Cause Mortality

L. Tian, Lee-Jen Wei, Chien-Chang Lee, 2021, Annals of Internal Medicine.

Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Akshay S. Desai, Lee-Jen Wei, J. McMurray, 2023, JAMA cardiology.

Association Between Bariatric Surgery and All-Cause Mortality

L. Tian, Lee-Jen Wei, Chien-Chang Lee, 2021, Annals of Internal Medicine.

Selecting appropriate endpoints for assessing treatment effects in comparative clinical studies for COVID-19

L. Tian, Lee-Jen Wei, K. Sheth, 2020, Contemporary Clinical Trials.

Prediction of cumulative incidence function under the proportional hazards model.

Lee-Jen Wei, L. J. Wei, S. Cheng, 1998, Biometrics.

On the C‐statistics for evaluating overall adequacy of risk prediction procedures with censored survival data

M. Pencina, H. Uno, Lee-Jen Wei, 2011, Statistics in medicine.

Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial.

Allen R. Chen, H. Uno, Lee-Jen Wei, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The accelerated failure time model: a useful alternative to the Cox regression model in survival analysis.

Lee-Jen Wei, L. J. Wei, 1992, Statistics in medicine.

Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy and Survival of Patients With Low-Risk Nasopharyngeal Carcinoma.

Lee-Jen Wei, E. Ludmir, T. Lin, 2023, JAMA.

Interpreting the Prognostic Value of Unrecognized Myocardial Infarction Among Older Adults.

Lee-Jen Wei, Z. McCaw, D. H. Kim, 2019, JAMA cardiology.

Interpreting the Survival Benefit From Neoadjuvant Chemoradiotherapy Before Surgery for Locally Advanced Squamous Cell Carcinoma of the Esophagus.

Lee-Jen Wei, Z. McCaw, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overall Survival in the Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer.

H. Uno, Lee-Jen Wei, M. Horiguchi, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

How to Summarize the Safety Profile of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy?

H. Uno, Lee-Jen Wei, Takahiro Hasegawa, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.